Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06792162 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

Name: PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer — clinical trial record (NCT06792162)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorPeking University Third Hospital

Started2023-04-20

View on ClinicalTrials.gov ↗

Record status

This record was last updated January 24, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.

Peking University Third Hospital

219 trials monitored

See 3 trials at risk

Gastric Cancer

1,194 trials monitored

See 60 trials at risk

Evaluate the safety and efficacy of PD-1 antibody Carilizumab combined with apatinib for the conversion therapy of unresectable stage III and IV dMMR gastric cancer.

Trial Details

NCT Number	NCT06792162
Lead Sponsor	Peking University Third Hospital
Conditions	Gastric Cancer
Enrollment	20 participants
Start Date	2023-04-20
Primary Completion	2026-04 (estimated)
Study Completion	2027-04 (estimated)
Updated on ClinicalTrials.gov	2025-01-24